+147.7%
AMKR vs MRNA
+34.8%
+112.9%
-65.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.4% | +5.4% | -0.9% | +4.2% |
| 7D | +8.3% | -1.1% | +9.4% | +8.3% |
| 30D | -6.8% | +126.1% | -132.9% | -13.1% |
| 3M | -31.9% | +190.0% | -222.0% | -41.7% |
| 6M | +18.4% | +157.2% | -138.9% | +4.2% |
| YTD | +31.7% | +388.2% | -356.5% | -1.9% |
| 1Y | +105.2% | +467.0% | -361.8% | +45.2% |
| 3Y | +147.7% | +36.1% | +111.7% | +105.4% |
| All | +147.7% | +34.8% | +112.9% | +105.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling